Yang Zhang

Dr. Yang Zhang

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
SXSicong Xie
Sicong Xie
YSYuwei Sun
Yuwei Sun
XZXuan Zhao
Xuan Zhao
YXYiqun Xiao
Yiqun Xiao
FZFei Zhou
Fei Zhou
YZYang Zhang
Yang Zhang
Anthracycline drugs mainly include doxorubicin, epirubicin, pirarubicin, and aclamycin, which are widely used to treat a variety of malignant tumors, such as breast cancer, gastrointestinal tumors, lymphoma, etc. With the accumulation of anthracycline drugs in the body, they can induce serious heart damage, limiting their clinical application. The mechanism by which anthracycline drugs cause cardiotoxicity is not yet clear. This review provides an overview of the different types of cardiac damage induced by anthracycline-class drugs and delves into the molecular mechanisms behind these injuries. Cardiac damage primarily involves alterations in myocardial cell function and pathological cell death, encompassing mitochondrial dysfunction, topoisomerase inhibition, disruptions in iron ion metabolism, myofibril degradation, and oxidative stress. Mechanisms of uptake and transport in anthracycline-induced cardiotoxicity are emphasized, as well as the role and breakthroughs of iPSC in cardiotoxicity studies. Selected novel cardioprotective therapies and mechanisms are updated. Mechanisms and protective strategies associated with anthracycline cardiotoxicity in animal experiments are examined, and the definition of drug damage in humans and animal models is discussed. Understanding these molecular mechanisms is of paramount importance in mitigating anthracycline-induced cardiac toxicity and guiding the development of safer approaches in cancer treatment.

18 March 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
LWLei Wang
Lei Wang
JMJiulong Ma
Jiulong Ma
CCChen Chen
Chen Chen
BLBin Lin
Bin Lin
SXSicong Xie
Sicong Xie
YZYang Zhang
Yang Zhang
Introduction: Due to the cardiotoxicity of pirarubicin (THP), it is necessary to investigate new compounds for the treatment of THP-induced cardiotoxicity. Isoquercitrin (IQC) is a natural flavonoid with anti-oxidant and anti-apoptosis properties. Thus, the present study aimed to investigate the influence of IQC on preventing the THP-induced cardiotoxicity in vivo and in vitro.Methods: The optimal concentration and time required for IQC to prevent THP-induced cardiomyocyte damage were determined by an MTT assay. The protective effect was further verified in H9c2 and HCM cells using dichlorodihydrofluorescein diacetate fluorescent probes, MitoTracker Red probe, enzyme-linked immunosorbent assay, JC-1 probe, and real time-quantitative polymerase chain reaction (RT-qPCR). Rats were administered THP to establish cardiotoxicity. An electrocardiogram (ECG) was performed, and cardiac hemodynamics, myocardial enzymes, oxidative stress indicators, and hematoxylin-eosin staining were studied. Voltage-dependent anion channel 1 (VDAC1), adenine nucleotide translocase 1 (ANT1), and cyclophilin D (CYPD) were detected by qRT-PCR, and the Phlpp1/AKT/Bcl-2 axis proteins were detected by western blot, confirming that IQC markedly increased cell viability and superoxide dismutase (SOD) levels, diminished the levels of ROS and MDA, and elevated mitochondrial function and apoptosis in vivo and in vitro.Results: Results showed that IQC reduced THP-induced myocardial histopathological injury, electrocardiogram (ECG) abnormalities, and cardiac dysfunction in vivo. IQC also decreased serum levels of MDA, BNP, CK-MB, c-TnT, and LDH, while increasing levels of SOD and GSH. We also found that IQC significantly reduced VDAC1, ANT1, and CYPD mRNA expression. In addition, IQC controlled apoptosis by modulating Phlpp1/AKT/Bcl-2 signaling pathways. IQC markedly increased H9c2 and HCM cell viability and SOD levels, diminished the levels of ROS and MDA, and elevated mitochondrial function in H9c2 and HCM cells to defend against THP-induced cardiomyocyte apoptosis in vitro. The AKT inhibitor IMQ demonstrated that IQC lacked antioxidant and anti-apoptotic properties. Moreover, our data showed that IQC regulates Phlpp1 expression, thereby influencing the expression levels of p-AKT, cytochrome c, caspase-3, caspase-9, Bcl-2, and Bax.Discussion: In conclusion, our results indicate that IQC protects the changes in mitochondrial membrane permeability in cardiomyocytes by regulating the Phlpp1/AKT/Bcl-2 signaling pathway, inhibits the release of cytc from the mitochondrial inner membrane to the cytoplasm, forms apoptotic bodies, induces cell apoptosis, and reduces THP induced cardiotoxicity.

16 September 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
SXSicong Xie
Sicong Xie
ZZZhiyi Zhou
Zhiyi Zhou
YZYu Zheng
Yu Zheng
CYChenshuo Yu
Chenshuo Yu
WKWeihan Kong
Weihan Kong
YZYang Zhang
Yang Zhang
Cancer metastasis and stem cells (CSCs) drive resistance and most cancer deaths. Novel agents like Thiolatia (PSMD14 inhibitor) suppress metastasis and enhance chemotherapy efficacy. Sulfarotene targets tumor-repopulating cells in liver cancer with low toxicity. PTC 209 utilizes the high affinity of modified hyaluronic acid nanoparticles for colorectal cancer to reverse CSC stemness in colorectal cancer. Platinum hybrids (HY1-Pt, Salvigenin-Pt) overcome resistance through dual mechanisms. Natural compound Cantharidin inhibits metastasis but requires toxicity optimization. These strategies emphasize specificity, nanodelivery, and combination therapies to reduce toxicity and resistance, highlighting precision oncology potential. Clinical validation remains critical for translation.

29 January 2026 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
SXSicong Xie
Sicong Xie
CCCheng Chang
Cheng Chang
TTThi Mai Tran
Thi Mai Tran
ZZZhiyi Zhou
Zhiyi Zhou
CYChenshuo Yu
Chenshuo Yu
YZYang Zhang
Yang Zhang
Diabetic cardiomyopathy (DCM) is a serious complication of end-stage diabetes that manifests as cardiac hypertrophy and heart failure. The present study performed a bioinformatics analysis to predict possible targets for aerobic exercise to improve DCM, and animal experiments were conducted to detect the relevant mechanisms. Oxidative stress (OS)-DCM-trained differentially expressed genes (DEGs) were retrieved from the GeneCards database and a Gene Expression Omnibus microarray dataset. Subsequently, a protein-protein interaction network was constructed to screen the hub genes of the OS-DCM-trained DEGs. In addition, a model of type 2 diabetes was established using streptozotocin and a high-fat diet. Rats were divided into the control, DCM and DCM plus exercise (DCME) groups. The DCME group underwent 8 weeks of moderate-intensity treadmill training. Assessment of cardiac function, myocardial enzymes and OS-related indicators in each group. Compared with the control group, the levels of BNP, CK-MB, c-TnT, LDH, MDA, LVEF, LVIDd, and LVIDs in the DCM group were significantly increased (P < 0.05), while SOD, GSH, and LVFS were significantly decreased (P < 0.05); The above indicators were significantly improved in DCME group rats (P < 0.05). In addition, the expression levels of target genes predicted to be associated with the aerobic exercise-induced improvement of DCM were detected and western blotting was used to determine the relevant signaling pathways. Bioinformatics analysis identified nine hub genes, which, according to Kyoto Encyclopedia of Genes and Genomes enrichment analysis, were mainly involved in “IL-17 signaling pathway,” “TNF signaling pathway,” “apoptosis” and “necroptosis.” Aerobic exercise improved the heart function and myocardial enzymes of the rats in the DCM group, reduced myocardial damage, and inhibited fibrosis and OS. Detection of the nine core genes revealed that only protein C ( PROC ) met the predicted trend; PROC expression was lower in the DCM group than that in the control group and was higher in the DCME group than that in the DCM group (P < 0.05). Further confirmation using western blotting suggested that aerobic exercise may improve DCM by activating the PROC/proteinase-activated receptor 1 (PAR1)/nuclear factor (erythroid-derived 2)-like 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling pathway. In conclusion, aerobic exercise may mitigate DCM by activating the PROC/PAR1/Nrf2/HO-1 signaling pathway. These findings could pave the way for further investigations into how exercise might regulate OS and influences DCM progression, providing novel insights into its diagnosis and prognosis.

30 September 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
SXSicong Xie
Sicong Xie
YSYuwei Sun
Yuwei Sun
XZXuan Zhao
Xuan Zhao
YXYiqun Xiao
Yiqun Xiao
FZFei Zhou
Fei Zhou
YZYang Zhang
Yang Zhang
There was a mistake in figure legend for Figure 1 as published. We omitted the permission information for the figure in the figure legend. The corrected figure legend for Figure 1 appears below. FIGURE 1 Stages in the course of Anthracycline-induced ventricular dysfunction. (1) Primary prevention is possible at this stage by reducing risk factors in high-risk populations (such as those receiving anticancer therapy). (2) Secondary prevention is possible at this stage to reduce the effects of the treatment-induced injury. (3) Secondary prevention is also possible at this stage. (4) Clinically significant conduction and rhythm abnormalities might be observed. (5) Radical therapies might be required at this stage (such as heart transplant) if there is failure of medical management. Preventive strategies are progressively less effective as the toxicity increases. Treatment strategies have a greater impact when used to treat themore-diseased heart, but have longer effects if initiated early. Reproduced with permission from " Early Diagnosis and Prediction of Anticancer Drug-induced Cardiotoxicity: From Cardiac Imaging to "Omics" Technologies" by Rosalinda Madonna, purchased and obtained a licence from Elsevier. There was a mistake in figure legend for Figure 2 as published. We omitted the permission information for the figure in the figure legend. The corrected figure legend for Figure 2 appears below. FIGURE 2 Mechanisms of action of doxorubicin (DOX). DOX intercalates between strands of DNA double helix. The formation of a ternary complex (TOP2-DOX-DNA) prevents enzyme turnover. The latter blocks the catalytic cycle after DNA is cleaved and before DNA relegation. DOX biotransformation results in the formation of ROS. Reproduced with permission from "Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity" by Raphaëlle Corremans, Rui Adão, Gilles W De Keulenaer, Adelino F Leite-Moreira and Carmen Brás-Silva, licensed under CC BY. There was a mistake in figure legend for Figure 3 as published. We omitted the permission information for the figure in the figure legend. The corrected figure legend for Figure 3 appears below. FIGURE 3 Doxorubicin (DOX) undergoes redoxcycling catalysed by NADPH-Cytochrome P-450 reductase. (A) The One-electron (1e-) reduction of the quinone compound leads to redox cycling and generation of superoxide anion radical. (B) O2-undergoes dismutation to form H2O2 either spontaneously or catalysed by superoxide dismutase. (C) H2O2 then reacts with the transition metal ion Fe2+, giving rise to -OH. Free Fe2+ is toxic to cells as catalyst in the formation of free radicals from ROS via the Fenton reaction. Last Name author1 et al. Frontiers Media SA 2 Reproduced with permission from "Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity" by Raphaëlle Corremans, Rui Adão, Gilles W De Keulenaer, Adelino F Leite-Moreira and Carmen Brás-Silva, licensed under CC BY. The original version of this article has been updated. There was a mistake in figure legend for Figure 4 as published. We omitted the permission information for the figure in the figure legend. The corrected figure legend for Figure 4 appears below. FIGURE 4 Anthracycline drugs induced changes in mitochondrial membrane permeability and induced cell death. (A) Mitochondrial permeability transition pore (MPTP) structure. It was recently proposed that the MPTP is generally considered to be a complex channel composed of several proteins, including voltage-dependent anion channel 1 (VDAC1) in the outer membrane, adenine nucleotide translocase 1 (ANT1) in the inner membrane, and cyclophilin D (CYPD) in the mitochondrial matrix. In addition, the MPTP can be regulated by other components, such as hexokinase (HK), creatine kinase (CK), and peripheral-type benzodiazepine receptors (PBR). Both antiapoptotic and proapoptotic members of the Bcl-2 family modulate the activity of MPTP (antiapoptotic members of the Bcl-2 family, including Bcl-2 and Bcl-XL, inhibit pore openingwhile proapoptotic Bcl-2 family members, such as Bax, Bak, and Bid, can induce MPT pore opening). Also, MPT pore opening can be inhibited by CypD ligands, such as cyclosporin A (CsA). The opening of MPTP leads to a collapse of transmembrane mitochondrial transmembrane potential and favors the release of apoptogenic proteins, such as cytochrome c (Cyt c). (B) A large component of DOX induced cardiotoxicity is mediated by a redox cycle on mitochondrial complex I. Increased ROS generation by DOX redox cycle has several negative consequences, such as mitochondrial transmembrane potential disruption, MPTP formation, ATP depletion, and peroxidation of cellular membranes. Marked mitochondrial morphological disturbances induced by DOX include cristae disruption, matrix disorganization, and mitochondrial fragmentation. MPTP -induced outer membrane rupture due to osmotic swelling or permeabilization of the mitochondrial outer membrane mediated by proapoptotic proteins including BAX can lead to the release of cyt c and AIF. DOX also interferes with topoisomerase II, inhibiting DNA replication and preventing the repair of damage DNA strands. Finally, persistent downregulation of gene expression can be another consequence of DOX toxicity. All of these events may lead to cell death. Reproduced with permission from "Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy" by Filipa S Carvalho, Ana Burgeiro, Rita Garcia, António J Moreno, Rui A Carvalho and Paulo J Oliveira, licensed under CC BY. The original version of this article has been updated. There was a mistake in figure legend for Figure 5 as published. We omitted the permission information for the figure in the figure legend. The corrected figure legend for Figure 5 appears below. FIGURE 5 Anthracycline drugs can cause mitochondrial dysfunction by inhibiting the...

1 July 2026 in Nano Research
Verified
Journal Article
Open access
PDF file
YLYi-Jie Li
Yi-Jie Li
YZYu-Yan Zhong
Yu-Yan Zhong
WWWei Wang
Wei Wang
CYChen-Shuo Yu
Chen-Shuo Yu
YZYang Zhang
Yang Zhang
QZQiang Zhao
Qiang Zhao
Organoid and Organ-on-a-Chip (OoC) are transformative in vitro platforms for biomedical research. A critical determinant of their physiological relevance is the faithful recapitulation of the native mechanical microenvironment, which governs cell behavior, morphogenesis, and maturation. Despite its recognized importance, a comprehensive review dedicated to the principles, design, and application of mechanical stimuli in these advanced systems remains limited. This review provides a systematic overview of this crucial aspect. We first elucidate the fundamental principles of mechanobiology, detailing how cells perceive and transduce mechanical cues such as fluid shear stress, substrate stiffness, and tensile strain. Subsequently, we analyze the implementation of mechanical control across diverse organoid culture methodologies, including scaffold-based, microcarrier, and advanced scaffold-free techniques. The review's core examines the application of engineered mechanical forces in various OoC models (e.g., lung, gut, heart, tumor), demonstrating how simulating physiological forces like cyclic stretching and peristalsis enhances biomimetic fidelity and functional maturation. Finally, we address key challenges and future prospects, including multi-scale stimuli integration, smart responsive materials, and mechanically coupled multi-organ systems. This work underscores the indispensable role of mechanical engineering in advancing organoid and OoC technologies for basic research and clinical applications. This review not only systematically synthesizes current progress but also proposes mechanobiological frameworks for the next generation of organoid and OoC systems.